

Clinical Trial Protocol

Iranian Registry of Clinical Trials

01 Jul 2026

Efficacy and complication of Duloxetine in attention deficit -hyperactivity disorder (ADHD) and comparison with Ritalin

Protocol summary

Summary

The purpose of this double blind clinical trial is to compare efficacy and side effects of Duloxetine and Ritalin in ADHD patients. In this study, 40 patients in the age range of 11-18 with ADHD will be randomly assigned into intervention or control groups. The patients in the intervention group will receive Duloxetine and control group will receive Ritalin. CANERS test for parents (summarized and edited format) and ADHD rating scale for parents and teacher will be performed before treatment and after 2, 4, 6 and 8 weeks and side effect questionnaire will be administered in 2, 4, 6 and 8 weeks after treatment.

General information

Acronym

IRCT registration information

IRCT registration number: **IRCT201110127462N2**
Registration date: **2011-10-19, 1390/07/27**
Registration timing: **prospective**

Last update:

Update count: **0**

Registration date

2011-10-19, 1390/07/27

Registrant information

Name

Mohammad Reza Mohammadi

Name of organization / entity

Tehran University of Medical Sciences

Country

Iran (Islamic Republic of)

Phone

+98 21 5541 3540

Email address

pprc@sina.tums.ac.ir

Recruitment status

Recruitment complete

Funding source

Tehran University of Medical Sciences

Expected recruitment start date

2011-10-23, 1390/08/01

Expected recruitment end date

2012-01-21, 1390/11/01

Actual recruitment start date

empty

Actual recruitment end date

empty

Trial completion date

empty

Scientific title

Efficacy and complication of Duloxetine in attention deficit -hyperactivity disorder (ADHD) and comparison with Ritalin

Public title

Efficacy and complication of Duloxetine in attention deficit -hyperactivity disorder (ADHD) and comparison with Ritalin

Purpose

Treatment

Inclusion/Exclusion criteria

Inclusion criteria: diagnostic criteria based on DSM IV for children with ADHD, age range 11-18, no consumption of any effective psychological drugs in past two week
Exclusion criteria: mental retardation, any other psychological disorders except for ODD, history of allergy to Duloxetine, serious medical conditions such as heart disease, uncontrolled convulsive disorder, systolic pressure upper than 125 mmhg or resting pulse less than 60 or more than 115 bit/m

Age

From **11 years** old to **18 years** old

Gender

Both

Phase

N/A

Groups that have been masked

No information

Sample size

Target sample size: 40

Randomization (investigator's opinion)

Randomized

Randomization description

Blinding (investigator's opinion)

Double blinded

Blinding description

Placebo

Not used

Assignment

Parallel

Other design features

Secondary Ids

empty

Ethics committees

1

Ethics committee

Name of ethics committee

Tehran University of Medical Sciences

Street address

Qods street, Keshavarz Blvd, Tehran

City

Tehran

Postal code

Approval date

2011-06-12, 1390/03/22

Ethics committee reference number

11148

Health conditions studied

1

Description of health condition studied

attention deficiency hyperactivity disorder

ICD-10 code

F90.0

ICD-10 code description

Disturbance of activity and attention

Primary outcomes

1

Description

attention deficiency hyperactivity disorder

Timepoint

Baseline, 2, 4, 6, 8 weeks after treatment

Method of measurement

CANERS test for parents (summerized and edited format) and ADHD rating scale for parents and teacher

Secondary outcomes

1

Description

drugs side effects

Timepoint

Baseline, 2,4,6,8 weeks after treatment

Method of measurement

side effect questionnaire

Intervention groups

1

Description

Intervention group: Duloxetine 1/4 capsule in the first week, 1/2 capsule in second week, 3/4 capsule in third week and 1 capsule in fourth week

Category

Treatment - Drugs

2

Description

Control group: according to Ritalin dosage 0.4-1.3 mg/kg, Ritalin 1 capsule for the first week (1/2 in the morning and 1/2 at noon), 2 capsule for the second week (1 capsule in the morning and 1 capsule at noon); if the weight of patient is more than 30 kg, 3 capsule will be daily prescribed for the third week (1 capsule in the morning and 1 capsule at noon and 1 capsule in the afternoon)

Category

Treatment - Drugs

Recruitment centers

1

Recruitment center

Name of recruitment center

Psychiatry and Psychology Research Center, Roozbeh Hospital

Full name of responsible person

Street address

City

Tehran

Sponsors / Funding sources

1

Sponsor

Name of organization / entity

Tehran University of Medical Sciences

Full name of responsible person

Mrs Moamaie

Street address

Qods street, Keshavarz Blvd, Tehran

City

Tehran
Grant name
Grant code / Reference number
Is the source of funding the same sponsor organization/entity?
Yes
Title of funding source
Tehran University of Medical Sciences
Proportion provided by this source
100
Public or private sector
empty
Domestic or foreign origin
empty
Category of foreign source of funding
empty
Country of origin
Type of organization providing the funding
empty

Person responsible for general inquiries

Contact

Name of organization / entity

Psychiatry research center, Tehran University of Medical Sciences

Full name of responsible person

Rozita Jalilian

Position

MD student

Other areas of specialty/work**Street address**

Psychiatry and Psychology Research Center, Roozbeh Hospital, South Kargar Avenue, after the Lashkar crossroads, Tehran, IRAN

City

Tehran

Postal code**Phone**

+98 21 5541 3540

Fax**Email**

rozita_jalilian@yahoo.com

Web page address

Person responsible for scientific inquiries

Contact

Name of organization / entity

Psychiatry and Psychology Research Center, Tehran University of Medical Sciences

Full name of responsible person

Mohammad Reza Mohammadi
Position
MD
Other areas of specialty/work
Street address
Psychiatry and Psychology Research Center, Roozbeh Hospital, South Kargar Avenue, after the Lashkar crossroads, Tehran, IRAN.
City
Tehran
Postal code
Phone
+98 21 5541 3540
Fax
Email
pprct@sina.tums.ac.ir
Web page address

Person responsible for updating data

Contact

Name of organization / entity

Psychiatry and Psychology Research Center

Full name of responsible person

Maryam Salmanian

Position

MS/Researcher

Other areas of specialty/work**Street address****City****Postal code****Phone****Fax****Email**

pprct@sina.tums.ac.ir

Web page address

Sharing plan

Deidentified Individual Participant Data Set (IPD)

empty

Study Protocol

empty

Statistical Analysis Plan

empty

Informed Consent Form

empty

Clinical Study Report

empty

Analytic Code

empty

Data Dictionary

empty